Diabetes Statistics 2026

589 million adults (20-79 years) are living with diabetes worldwide – 1 in 9.

The total number of adults with diabetes is predicted to rise to 853 million by 2050 – 1 in 8.

4 in 5 adults with diabetes (81%) live in low and middle-income countries.

In 2022, an estimated 828 million (95% credible interval [CrI] 757–908) adults (those aged 18 years and older) had diabetes, an increase of 630 million (554–713) from 1990.

The number of people living with diabetes rose from 200 million in 1990 to 830 million in 2022.

In 2022, 14% of adults aged 18 years and older were living with diabetes, an increase from 7% in 1990.

More than half a billion people are living with diabetes worldwide, affecting men, women, and children of all ages in every country, and that number is projected to more than double to 1.3 billion people in the next 30 years, with every country seeing an increase, as published today in The Lancet.

Number of adults (20–79 years) with diabetes in China (CN) 2000 22.6 million 2011 90.0 million 2024 148.0 million 2050 168.3 million

Number of adults (20–79 years) with diabetes in India (IN) 2000 32.7 million 2011 61.3 million 2024 89.8 million 2050 156.7 million

Number of adults (20–79 years) with diabetes in United States of America (US) 2000 15.3 million 2011 23.7 million 2024 38.5 million 2050 43.0 million

India (212 million, 175–250) and China (148 million, 103–202) accounted for the largest proportion of this number, followed by the USA, Pakistan, Indonesia, and Brazil.

The study further reveals substantial global differences in diabetes rates, with the prevalence of diabetes among adults aged 18 and older around 20% in the WHO South-East Asia and the Eastern Mediterranean Regions.

We estimate that almost 6 million people in the UK are living with diabetes, which is an all-time high.

Our data shows that over 4.7 million people in the UK live with diabetes diagnoses.

Total diabetes 40.1 million Estimated number of people with diagnosed or undiagnosed diabetes in the United States, 2023

Diagnosed diabetes 29.1 million Estimated number of people with diagnosed diabetes in the United States, including 28.8 million adults aged ≥18 years

During August 2021–August 2023, the prevalence of total diabetes was 15.8%, diagnosed diabetes was 11.3%, and undiagnosed diabetes was 4.5% in U.S. adults.

Men had a higher prevalence of total and diagnosed diabetes (18.0% and 12.9%, respectively) compared with women (13.7% and 9.7%).

The prevalence of total diabetes increased from 3.6% in adults ages 20–39 to 17.7% for ages 40–59 and 27.3% for age 60 and older (Figure 2, Table 2).

The prevalence of total diabetes increased from 6.8% in adults in the underweight or normal weight category to 12.3% in those in the overweight category and 24.2% in adults with obesity (Figure 3, Table 3).

The age-adjusted prevalence of total diabetes increased from 9.7% in 1999–2000 to 14.3% in August 2021–August 2023 (Figure 5, Table 5).

Meanwhile, diagnoses of diabetes — a lifetime disease that can be managed but not cured — have now reached an all-time high of 13.8%.

An estimated 43% of adults living with diabetes (252 million people) are undiagnosed.

635 million adults worldwide (1 in 8) have impaired glucose tolerance and 488 million have impaired fasting glucose (1 in 11) placing them at high risk of type 2 diabetes.

Undiagnosed diabetes 27.6% Estimated percentage of adults aged ≥18 years with diabetes who are undiagnosed, representing 11.0 million people

Prediabetes 115.2 million Estimated number of U.S. adults aged ≥18 years with prediabetes

Prediabetes: ≥65 years 31.3 million Estimated number of people aged 65 years or older (52.1%) with prediabetes

We estimate that almost 1.3 million people are currently living with type 2 diabetes but are yet to be diagnosed.

In 2022, 445 million (95% CrI 401–496) adults aged 30 years or older with diabetes did not receive treatment (59% of adults aged 30 years or older with diabetes), 3·5 times the number in 1990.

30% of those with untreated diabetes (133 million, 109–160) were in India, more than 50% greater than the next largest number of people with untreated diabetes, which was in China (78 million, 51–112; figure 3 ), because treatment coverage was higher in China than in India.

The study estimates that T1D will affect 9.5 million people globally in 2025 (up by 13% since 2021), and this number is predicted to rise to 14.7 million in 2040.

The study predicts that 513,000 new cases of T1D will be diagnosed worldwide in 2025, of which 43% (222,000) will be people younger than 20 years old.

Globally, 174,000 people are projected to die from T1D in 2025.

Type 1 diabetes 2.1 million Estimated number of people with diagnosed type 1 diabetes in the United States, including 1.8 million adults aged ≥20 years and 314,000 children and adolescents younger than age 20 years

Almost all global cases (96%) are type 2 diabetes (T2D); all 16 risk factors studied were associated with T2D.

Nine out of 10 people living with diabetes in England have Type 2, which is largely preventable.

Around 8% of people with a diabetes diagnosis have type 1 diabetes.

Diabetes caused 3.4 million deaths in 2024 – 1 every 9 seconds.

In 2023, diabetes was the direct cause of 2.0 million deaths and 44% of all deaths due to diabetes occurred before the age of 70 years.

Number of deaths: 94,445 Deaths per 100,000 population: 27.8 Cause of death rank: 7

Diabetes was responsible for an estimated USD 1.015 trillion in global health expenditure in 2024.

The Economic Report, which is published every five years, found that the total annual cost of diabetes in 2022 is $412.9 billion, including $306.6 billion in direct medical costs and $106.3 billion in indirect costs.

People with diagnosed diabetes now account for one of every four healthcare dollars spent in the U.S.

Spending on insulin tripled in the past 10 years—increasing from $8 billion in 2012 to $22.3 billion in 2022.

The total cost of diabetes to the NHS in the UK is an estimated £10.7 billion with 60% of that spending on the costs of diabetes complications.

About one in eight adults (12%) say that they are currently taking a GLP-1 drug such as Ozempic or Wegovy either to lose weight or treat a chronic condition, an increase from 18 months ago, though the high costs of the medications remain a concern, a new KFF Health Tracking Poll finds.

GLP-1 drugs have been used by large shares of adults who say they have been diagnosed with diabetes (57% have ever used the drug, including 45% who are currently using), heart disease (40% ever, 29% currently), or as obese or overweight in the past five years (34% ever, 23% currently).

The poll – fielded prior to President Trump’s announcement last week related to the cost and coverage of GLP-1 drugs – finds that about half of GLP-1 users (56%), including a similar share among those with insurance (55%), say that it was difficult to afford these drugs.

In 2024, 26.5% of adults with diagnosed diabetes used GLP-1 injectables to lower blood sugar or lose weight.

The percentage of adults who report taking this class of medicine specifically for weight loss has increased to 12.4%, compared with 5.8% in February 2024 when Gallup first measured it.

Among those who have been diagnosed with diabetes, 14.1% report using these drugs for weight loss purposes, slightly higher than the general adult population.

Two million Part D enrollees took Ozempic, which was approved by the FDA in 2017 to treat type 2 diabetes, up from fewer than 150,000 in 2019 (Figure 1).

Over 13,000 people were enrolled onto the NHS Type 2 Diabetes Path to Remission Programme, also known as the ‘soups and shakes’ diet, in 2024-25 – almost double the previous year (6,401 in 2023-24) and the highest ever.